LUMOXITI (moxetumomab pasudotox-tdfk)

MEDICAL BENEFIT: INTRAVENOUS ADMINSTRATION

Indications for Prior Authorization:

  • Indicated in adults with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog

Patients must meet the following criteria for the indication(s) above:

  • Patient is ≥ 18 years of age, AND
  • Prescribed by or in consultation with an oncologist or hematologist, AND
  • Diagnosis of relapsed/refractory hairy cell leukemia confirmed by chart note documentation, AND
  • Patient has received > 2 prior systemic therapies, including therapy with a purine analog (cladribine and/or pentostatin), AND
  • Patient has an estimated creatinine clearance > 30 mL/min

Dosing:

  • 0.04 mg/kg as a 30-minute IV infusion on days 1, 3, 5 of each 28-day cycle. 
  • Continue Lumoxiti™ treatment for a maximum of 6 cycles, disease progression, or unacceptable toxicity

Approval:

  • 6 months (maximum 6 total cycles)

Last review date: April 16, 2019

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone